NextCell Pharma AB (OSTO:NXTCL) Ending Cash Position : kr26.34 Mil (As of Feb. 2025)

View and export this data going back to 2017. Start your Free Trial

What is NextCell Pharma AB Ending Cash Position?

NextCell Pharma AB's Ending Cash Position for the quarter that ended in Feb. 2025 was kr26.34 Mil.

NextCell Pharma AB's quarterly Ending Cash Position declined from Aug. 2024 (kr46.79 Mil) to Nov. 2024 (kr34.12 Mil) and declined from Nov. 2024 (kr34.12 Mil) to Feb. 2025 (kr26.34 Mil).

NextCell Pharma AB's annual Ending Cash Position declined from Aug. 2022 (kr97.12 Mil) to Aug. 2023 (kr50.03 Mil) and declined from Aug. 2023 (kr50.03 Mil) to Aug. 2024 (kr46.79 Mil).

NextCell Pharma AB Ending Cash Position Historical Data

The historical data trend for NextCell Pharma AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCell Pharma AB Ending Cash Position Chart

NextCell Pharma AB Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Ending Cash Position

Get a 7-Day Free Trial

21.96

139.17

97.12

50.03

46.79

NextCell Pharma AB Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
Ending Cash Position	Get a 7-Day Free Trial															30.39	20.80	46.79	34.12	26.34

NextCell Pharma AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

NextCell Pharma AB's Ending Cash Position for the fiscal year that ended in Aug. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	50.026	+	-3.235
	=	46.79

NextCell Pharma AB's Ending Cash Position for the quarter that ended in Feb. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	34.123	+	-7.785
	=	26.34

NextCell Pharma AB Ending Cash Position Related Terms

Thank you for viewing the detailed overview of NextCell Pharma AB's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCell Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCell Pharma AB (OSTO:NXTCL) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

65G:Germany

Address

Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157

Website

http://www.nextcellpharma.com

NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.

NextCell Pharma AB Headlines

No Headlines